The Cutaneous Oncology Program at Moffitt Cancer Center specializes in the evaluation and treatment of patients with cancers of the skin – melanoma, basal and squamous cell carcinoma, Merkel cell carcinoma, dermatofibrosarcoma protuberans and other skin tumors.
The interdisciplinary team of skin cancer specialists at the Cutaneous Oncology Program provide comprehensive care for patients. Screening, diagnosis, staging and treatment for skin cancer are provided, as well as long-term follow-up both at Moffitt and in coordination with a patient’s primary physician closer to home. As a comprehensive skin cancer hospital, Moffitt's Cutaneous Oncology Program’s comprehensive care includes the latest investigational treatments for melanoma. Program physicians have been pioneers in developing and defining the role of lymphatic mapping and sentinel node biopsy for staging of patients with clinically negative nodes, as well as investigating adjuvant therapy for both node-negative and node-positive patients. Surgical treatment of selected patients with in-transit and metastatic melanoma also is a fundamental part of the approach to patients with more advanced disease.
The Cutaneous Oncology Program at Moffitt offers the most current diagnostic procedures available, including lymphatic mapping and sentinel lymph node biopsy.
- College and medical students interested in research opportunities, please click here.
Our consultation service provides expert consultation and second opinion in a broad range of subspecialties, including dermatopathology. Comprehensive consultation and case review with a diagnostic expert entails routine H & E interpretation, in our state-of-the-art, full-service laboratory, and ability to utilize a large array of immunohistochemical markers including estrogen receptor, progesterone receptor, HER-2/neu, EGFR mutation, KRAS, BRAF, HPV, etc. Rapid turnaround time with immediate faxing of final report and immediate notification of minor/major discrepancies occurs.
Click here for more info: Pathology Services.